Shots:

• The approval is based on P-lll ETHOS involve the assessing of Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) vs Bevespi Aerosphere and PT009 in adult patients with mod. to sev. COPD. P-III KRONOS study also supported the approval
• The study showed a reduction in rate of mod. or sev. exacerbations. EMA’s CHMP has recommended the MAA for Trixeo Aerosphere in Oct’2020
• Trixeo Aerosphere is a single-inhaler- fixed-dose triple-combination of formoterol fumarate LABA- LAMA- with budesonide- an ICS- and delivered in a pressurized metered-dose inhaler. The approval marks the fourth major approval of the therapy

 ­ Ref: AstraZeneca | Image: The Scientist Magazine